Skip to main content

Find Clinical Trials

Home
Conditions
Neoplasm, Residual

Clinical trial condition

Neoplasm, Residual

Explore clinical trials studying Neoplasm, Residual. Study availability and eligibility vary by location and protocol.

194 public trials 80 recruiting studies

Refine in advanced search Browse all conditions

Neoplasm, Residual trial results

Recruiting

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

NCT07148180

Conditions: Acute Myeloid Leukaemia (AML), Blood Cancer, Blood Cancers, +13 more
Locations: Brigham and Women's Hospital Boston, Massachusetts, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Recruiting

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

NCT06693830

Conditions: Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Hemic and Lymphatic Diseases, +15 more
Locations: Columbia University New York, United States

View Trial Details

Recruiting

European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma

NCT07356882

Conditions: Classical Hodgkin Lymphoma, Neoplasm, Residual, Neoplasms, +3 more
Locations: Pediatric Hematology and Oncology Department Paris, France

View Trial Details

Recruiting

Caris Biorepository Research Protocol

NCT01499394

Conditions: Cancer, Early Detection of Cancer, Minimal Residual Disease, +5 more
Locations: University of South Alabama Mobile, Alabama, United States

Southwest Medical Imaging Scottsdale, Arizona, United States

St. Bernards Medical Center Jonesboro, Arkansas, United States

CARTI Cancer Center Little Rock, Arkansas, United States

View all 38 locations

View Trial Details

Recruiting

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

NCT07025785

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +11 more
Locations: UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States

View Trial Details

Recruiting

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

NCT04991103

Conditions: Amyloidosis, Blood Protein Disorders, Cardiovascular Diseases, +20 more
Locations: University of Alabama at Birmingham Birmingham, Alabama, United States

View Trial Details

Recruiting

To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT

NCT07280494

Conditions: CD7+ T-ALL/LBL, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations: Peking University People's Hospital Beijing, China

View Trial Details

Recruiting

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma

NCT05595408

Conditions: Muscle Invasive Upper Tract Urothelial Carcinoma, Neoplasm, Residual, Neoplasms, +3 more
Locations: Renji Hospital Shanghai, Shanghai Municipality, China

View Trial Details

Recruiting

Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)

NCT04707300

Conditions: Hematologic Diseases, Hematologic Malignancy, Hematologic Neoplasms, +11 more
Locations: Hôpital Saint Louis Paris, France

Service d'Hématologie et thérapie cellulaire / CHU of Bordeaux Pessac, France

IUCT Oncopole Toulouse Toulouse, France

Institut Gustave Roussy Villejuif, France

View Trial Details

Recruiting

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

NCT07059975

Conditions: Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations: Texas Children's Cancer and Hematology Center Houston, Texas, United States

View Trial Details